Skip to content

Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis

Prospective Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03977779
Acronym
ARCHIMEDE
Enrollment
46
Registered
2019-06-06
Start date
2022-01-20
Completion date
2024-12-15
Last updated
2024-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Stricture, Obstructive Jaundice, Sphincter of Oddi Dysfunction

Keywords

biodegradable stent, Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis

Brief summary

The use of an endoprothesis in a pancreatic duct is a measure to minimize the incidence and severity of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis. In this study we will evaluate the use of a Biodegradable Endoprothesis: Archimede Fast Biodegradable Pancreatic Stent in patients with high risk of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis.The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography. The efficacy and the security of the device will be evaluated.

Interventions

DEVICEPlacement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography

The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography

Sponsors

Institut Paoli-Calmettes
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age\>18 years * Patients at risk of developing a Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis (procedure and/or patient-related risk factors

Exclusion criteria

* Pregnant or breastfeeding women * Recent diagnosis (\<1 month) of acute pancreatitis * contraindication to endoscopy * Hypersensitivity to indomethacine

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients with a complete clearance of the biodegradable stentDay 15The degradation of the stent will be evaluated both duodenoscopy/fluoroscopy and endoscopy 15 days after its placement

Countries

France

Contacts

Primary ContactDominique Genre, MD
drci.up@ipc.unicancer.fr+33491223778
Backup ContactMarc Giovannini, MD
giovanninim@ipc.unicancer.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026